Kyntra Bio Q2: $95.7M Cash, Roxadustat Phase 3 Start Set for 4Q
KYNB is trading near its 52-week low of $6.32 (10.0% above the low) on light trading volume (0.2× avg).
Summary
Kyntra Bio's Q2 earnings show a $12.0M net income, $95.7M cash runway into 2028, and two pivotal clinical milestones set for Q4 2026.
Key Events · Earnings and Guidance · KYNB
-
Q2 Net Income of $12.0M
Net income from continuing operations was $12.0 million, or $2.96 per share, compared to a net loss of $13.7 million a year ago, driven by a $30.9 million gain on deconsolidation of a subsidiary.
-
Cash Runway into 2028
Cash, cash equivalents, investments, and accounts receivable totaled $95.7 million as of June 30, 2026, which the company expects to fund operating plans into 2028.
-
Roxadustat Phase 3 Start in 4Q 2026
The Phase 3 protocol for roxadustat in LR-MDS with high transfusion burden has been finalized, with the goal to initiate the registrational study in the fourth quarter of 2026.
-
FG-3246 Interim Analysis in 4Q 2026
Enrollment in the Phase 2 monotherapy trial of FG-3246 in mCRPC continues, with interim analysis on track for the fourth quarter of 2026.
Analysis · KYNB · Life Sciences
Kyntra Bio reported Q2 results with a net income of $12.0 million, driven by a $30.9 million gain on deconsolidation of a subsidiary. The company disclosed $95.7 million in cash and investments, which it expects to fund operations into 2028. Two key clinical milestones are on track for the fourth quarter: initiation of the Phase 3 roxadustat trial in LR-MDS and interim analysis of the Phase 2 FG-3246 trial in mCRPC. This provides clarity on near-term catalysts and financial runway.
At the time of this filing, KYNB was trading at $6.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $28.5M. The 52-week trading range was $6.32 to $12.60. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.